share_log

Altimmune | 10-Q: Q2 2024 Earnings Report

Altimmune | 10-Q: Q2 2024 Earnings Report

Altimmune | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/09 04:10

Moomoo AI 已提取核心信息

Altimmune reported a net loss of $24.6 million for Q2 2024, compared to $16.1 million in Q2 2023, as research and development expenses increased 60% to $21.2 million. The higher R&D costs were primarily driven by an $8.7 million increase related to the IMPACT Phase 2b trial in MASH. Cash, cash equivalents, and short-term investments totaled $164.9 million as of June 30, 2024.The company's lead product candidate pemvidutide showed promising body composition results from its 48-week MOMENTUM Phase 2 obesity trial, with 78.1% of weight loss derived from adipose tissue. Management discontinued further development of HepTcell in March 2024 after determining the Phase 2 trial response was insufficient to warrant advancement.General and administrative expenses rose 18% to $5.6 million, including $1.0 million in incremental stock-based compensation due to stock award modifications. The company believes its current cash position is sufficient to fund operations for at least 12 months, though it continues to pursue additional financing options to support planned clinical trials.
Altimmune reported a net loss of $24.6 million for Q2 2024, compared to $16.1 million in Q2 2023, as research and development expenses increased 60% to $21.2 million. The higher R&D costs were primarily driven by an $8.7 million increase related to the IMPACT Phase 2b trial in MASH. Cash, cash equivalents, and short-term investments totaled $164.9 million as of June 30, 2024.The company's lead product candidate pemvidutide showed promising body composition results from its 48-week MOMENTUM Phase 2 obesity trial, with 78.1% of weight loss derived from adipose tissue. Management discontinued further development of HepTcell in March 2024 after determining the Phase 2 trial response was insufficient to warrant advancement.General and administrative expenses rose 18% to $5.6 million, including $1.0 million in incremental stock-based compensation due to stock award modifications. The company believes its current cash position is sufficient to fund operations for at least 12 months, though it continues to pursue additional financing options to support planned clinical trials.
Altimmune报告称2024年第二季度净亏损为2460万美元，较2023年第二季度的1610万美元有所增加，研究和开发费用增加了60%，达到了2120万美元。研发成本的增加主要是由于与MASH中的IMPACt 20亿试验相关的增加870万美元。截止到2024年6月30日，公司现金、现金等价物和短期投资总额为16490万美元。公司主要产品候选药物pemvidutide在其48周的MOMENTUm第二期肥胖试验中显示了令人鼓舞的身体成分结果，其中78.1%的体重减轻来自脂肪组织。管理层在2024年3月决定终止HepTcell的进一步开发，因为确定第二期试验的反应不足以支持其推进。一般和行政费用增加了18%，达到了560万美元，其中包括由于股权奖励修改而增加的100万美元的股票薪酬。公司认为其当前的现金状况足以支持至少12个月的运营，尽管它仍在寻求额外的融资期权来支持计划中的临床试验。
Altimmune报告称2024年第二季度净亏损为2460万美元，较2023年第二季度的1610万美元有所增加，研究和开发费用增加了60%，达到了2120万美元。研发成本的增加主要是由于与MASH中的IMPACt 20亿试验相关的增加870万美元。截止到2024年6月30日，公司现金、现金等价物和短期投资总额为16490万美元。公司主要产品候选药物pemvidutide在其48周的MOMENTUm第二期肥胖试验中显示了令人鼓舞的身体成分结果，其中78.1%的体重减轻来自脂肪组织。管理层在2024年3月决定终止HepTcell的进一步开发，因为确定第二期试验的反应不足以支持其推进。一般和行政费用增加了18%，达到了560万美元，其中包括由于股权奖励修改而增加的100万美元的股票薪酬。公司认为其当前的现金状况足以支持至少12个月的运营，尽管它仍在寻求额外的融资期权来支持计划中的临床试验。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Portage Biotech
    PRTG
    -- 9.600
    莱斯康制药
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点